目的探讨尿IgG/尿肌酐(UGCR)、24 h尿蛋白定量(24 h UP)、尿蛋白定量/尿肌酐(UPCR)在预测IgA血管炎肾炎(IgAVN)患儿肾脏病理进展中的价值。方法选取2018年1月—2022年10月收治的IgAVN患儿234例,均采集24 h尿液标本检测24 h UP。根据肾...目的探讨尿IgG/尿肌酐(UGCR)、24 h尿蛋白定量(24 h UP)、尿蛋白定量/尿肌酐(UPCR)在预测IgA血管炎肾炎(IgAVN)患儿肾脏病理进展中的价值。方法选取2018年1月—2022年10月收治的IgAVN患儿234例,均采集24 h尿液标本检测24 h UP。根据肾小球损伤程度不同将IgAVN患儿分为Ⅱ级47例、Ⅲ级175例、Ⅳ级12例,分析UGCR、24 h UP、UPCR与肾脏病理分级的相关性,通过受试者工作特征曲线分析上述指标预测肾脏IgAVN病理分级进展为Ⅲ级及以上的价值。结果肾脏病理分级Ⅲ级、Ⅳ级患儿UGCR、24 h UP、UPCR水平高于Ⅱ级患儿(P<0.01)。UGCR、24 h UP、UPCR与病理分级呈正相关,但相关性较弱(r=0.500、0.451、0.356,P<0.01)。UGCR、24 h UP和UPCR对IgAVN患儿肾脏病理分级进展为Ⅲ级及以上均具有预测价值,且三者联合检测预测价值更高(曲线下面积>0.9,P<0.01)。结论UGCR联合24 h UP、UPCR对IgAVN肾脏病理分级进展为Ⅲ级及以上的预测价值更高。展开更多
This observational prospective study was conducted on 25 patients who had received a full 3-dose COVID-19 vaccination scheme with a follow-up ranging from 12 to 19 months after the last injection. The aim of the study...This observational prospective study was conducted on 25 patients who had received a full 3-dose COVID-19 vaccination scheme with a follow-up ranging from 12 to 19 months after the last injection. The aim of the study was focused on a single biological indicator the anti-spike IgG antibody titer. The age of the patients ranged from 51 to 85 years old. 15 out 25 patients (60%) presented a comorbidity. Our data showed a persistent positive anti-spike IgG antibodies titer ranging from 105 to 5680 BAU/mL (mean: 2661 BAU/mL) in all patients. In view of these results, systematic administration of a SARS-CoV-2 vaccine booster is questionable and should be individually tailored according to the patient medical condition and the anti-spike IgG antibody level.展开更多
Objective Pertussis cases have increased markedly since 2018 in Guangxi.The aim of this study was to evaluate antibody levels and the infection status of pertussis in the resident population.Method A total of 10,215 s...Objective Pertussis cases have increased markedly since 2018 in Guangxi.The aim of this study was to evaluate antibody levels and the infection status of pertussis in the resident population.Method A total of 10,215 serum samples from residents were collected from August-November 2018 and tested for anti-pertussis IgG and toxin IgG using the enzyme-linked immunosorbent assay(ELISA).Results Of the collected samples,1,833(17.94%)tested positive for anti-pertussis IgG,with the median concentration of 16.06 IU/mL.Antibody level<10 IU/mL accounted for more than 60%in children under 4 years of age,but declined with age,whereas the percentages of the other three levels(10-40,40-50,and≥50 IU/mL)increased almost with age(P<0.001).Moreover,7,924 samples were selected for anti-pertussis toxin IgG,of which 653(8.24%)tested positive(≥40 IU/mL)with the median concentration of 5.89 IU/mL,and 204 participants(2.56%)had recent pertussis infection(≥100 IU/mL).Among the different age groups,the highest rates of positivity and recent infection were observed at 11-20 years of age,the lowest positivity rate at 5 years of age,and the lowest recent infection rate at 4 years of age(P<0.001,P=0.005,respectively).Conclusion The survey results showed that all age groups in Guangxi lacked immunity against pertussis,which was one of the main factors contributing to the resurgence of pertussis in 2018.In addition,the prevalence of pertussis is relatively high in Guangxi,and its incidence is seriously underestimated,especially in adolescents and adults.展开更多
With gene engineering EB virus membrane antigen as the diagnostic antigen, indirect immunofluo-rescence (IF) assay was used to detect IgA antibody against EB virus membrane antigen (MA-IgA) in sera from 202 nasopharyn...With gene engineering EB virus membrane antigen as the diagnostic antigen, indirect immunofluo-rescence (IF) assay was used to detect IgA antibody against EB virus membrane antigen (MA-IgA) in sera from 202 nasopharyngeal carcinoma (NPC) patients and 315 controls (normal and patients with other tumors). MA-IgA antibody was positive in 96.8% of the pretreatment NPC patients with a GMT of 1:36.3. MA-IgA detection by this method was more sensitive than EA-IgA detection by IE. In contrast, patients with tumors other than NPC were negative for MA-IgA antibody. 9.1% of VCA-IgA positive persons were MA-IgA positive with a GMT of less than 1:5. No MA-IgA positive was found in VCA-IgA negatives. The results indicated that this method was relatively specific. In the treatment group, the positive rate and GMT of MA-IgA antibody declined with increase in survival time and the decline was faster than VCA-IgA. When recurrence or distant metastasis developed, similar to VCA-IgA and EA-IgA antibodies, the positive rate and GMT of MA-IgA antibody increased to its pretreatment level. Therefore, MA-IgA detection might be valuable in the early diagnosis and monitor of NPC.展开更多
文摘目的探讨尿IgG/尿肌酐(UGCR)、24 h尿蛋白定量(24 h UP)、尿蛋白定量/尿肌酐(UPCR)在预测IgA血管炎肾炎(IgAVN)患儿肾脏病理进展中的价值。方法选取2018年1月—2022年10月收治的IgAVN患儿234例,均采集24 h尿液标本检测24 h UP。根据肾小球损伤程度不同将IgAVN患儿分为Ⅱ级47例、Ⅲ级175例、Ⅳ级12例,分析UGCR、24 h UP、UPCR与肾脏病理分级的相关性,通过受试者工作特征曲线分析上述指标预测肾脏IgAVN病理分级进展为Ⅲ级及以上的价值。结果肾脏病理分级Ⅲ级、Ⅳ级患儿UGCR、24 h UP、UPCR水平高于Ⅱ级患儿(P<0.01)。UGCR、24 h UP、UPCR与病理分级呈正相关,但相关性较弱(r=0.500、0.451、0.356,P<0.01)。UGCR、24 h UP和UPCR对IgAVN患儿肾脏病理分级进展为Ⅲ级及以上均具有预测价值,且三者联合检测预测价值更高(曲线下面积>0.9,P<0.01)。结论UGCR联合24 h UP、UPCR对IgAVN肾脏病理分级进展为Ⅲ级及以上的预测价值更高。
文摘This observational prospective study was conducted on 25 patients who had received a full 3-dose COVID-19 vaccination scheme with a follow-up ranging from 12 to 19 months after the last injection. The aim of the study was focused on a single biological indicator the anti-spike IgG antibody titer. The age of the patients ranged from 51 to 85 years old. 15 out 25 patients (60%) presented a comorbidity. Our data showed a persistent positive anti-spike IgG antibodies titer ranging from 105 to 5680 BAU/mL (mean: 2661 BAU/mL) in all patients. In view of these results, systematic administration of a SARS-CoV-2 vaccine booster is questionable and should be individually tailored according to the patient medical condition and the anti-spike IgG antibody level.
基金approved by the Ethics Committee of the Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention(GXIRB 2018-0005),and the participants signed informed consent forms.
文摘Objective Pertussis cases have increased markedly since 2018 in Guangxi.The aim of this study was to evaluate antibody levels and the infection status of pertussis in the resident population.Method A total of 10,215 serum samples from residents were collected from August-November 2018 and tested for anti-pertussis IgG and toxin IgG using the enzyme-linked immunosorbent assay(ELISA).Results Of the collected samples,1,833(17.94%)tested positive for anti-pertussis IgG,with the median concentration of 16.06 IU/mL.Antibody level<10 IU/mL accounted for more than 60%in children under 4 years of age,but declined with age,whereas the percentages of the other three levels(10-40,40-50,and≥50 IU/mL)increased almost with age(P<0.001).Moreover,7,924 samples were selected for anti-pertussis toxin IgG,of which 653(8.24%)tested positive(≥40 IU/mL)with the median concentration of 5.89 IU/mL,and 204 participants(2.56%)had recent pertussis infection(≥100 IU/mL).Among the different age groups,the highest rates of positivity and recent infection were observed at 11-20 years of age,the lowest positivity rate at 5 years of age,and the lowest recent infection rate at 4 years of age(P<0.001,P=0.005,respectively).Conclusion The survey results showed that all age groups in Guangxi lacked immunity against pertussis,which was one of the main factors contributing to the resurgence of pertussis in 2018.In addition,the prevalence of pertussis is relatively high in Guangxi,and its incidence is seriously underestimated,especially in adolescents and adults.
文摘With gene engineering EB virus membrane antigen as the diagnostic antigen, indirect immunofluo-rescence (IF) assay was used to detect IgA antibody against EB virus membrane antigen (MA-IgA) in sera from 202 nasopharyngeal carcinoma (NPC) patients and 315 controls (normal and patients with other tumors). MA-IgA antibody was positive in 96.8% of the pretreatment NPC patients with a GMT of 1:36.3. MA-IgA detection by this method was more sensitive than EA-IgA detection by IE. In contrast, patients with tumors other than NPC were negative for MA-IgA antibody. 9.1% of VCA-IgA positive persons were MA-IgA positive with a GMT of less than 1:5. No MA-IgA positive was found in VCA-IgA negatives. The results indicated that this method was relatively specific. In the treatment group, the positive rate and GMT of MA-IgA antibody declined with increase in survival time and the decline was faster than VCA-IgA. When recurrence or distant metastasis developed, similar to VCA-IgA and EA-IgA antibodies, the positive rate and GMT of MA-IgA antibody increased to its pretreatment level. Therefore, MA-IgA detection might be valuable in the early diagnosis and monitor of NPC.
